Cole Schmidtknecht, 22, couldn't pay for his daily inhaler due to the “prohibitively expensive” price increase. Two weeks ...
A clinically and functionally relevant definition of an asthma exacerbation will be invaluable in the assessment of the severity of such an event and the streamlining of the steps necessary to ...
Of four treatment response measures recorded at 6 months of mepolizumab treatment, an Asthma Control Questionnaire score was ...
Pre-treatment disease trajectories in severe asthma impact treatment-related outcomes, according to a study by Johannes ...
GSK plc (LSE/NYSE: GSK) today announced that new drug applications have been accepted for review by the China National Medical Products Administration and submitted to the Japanese Ministry of Health, ...
Depemokimab is a follow-up to GSK's Nucala (mepolizumab), a once-monthly IL-5 inhibitor approved for severe asthma, CRSwNP, ...
Environmental and Socioeconomic Factors Fuel Respiratory Health Disparities in Rural and Urban Areas
Research highlights how poor housing, pollution, and green spaces affect respiratory health, with rural and urban communities ...
GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency has accepted for review the Marketing Authorisation Application for the use of depemokimab in two indications. The submitted ...
GSK plc has announced that new drug applications have been accepted for review by the China National Medical Products ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback